Successful Treatment of Vitiligo with Crisaborole 2% Ointment

Main Article Content

William Tausend
Paige Hoyer
Morgan Arnold
Keith Wagner
Lindy Ross
Brandon P Goodwin
Janice M Wilson


Vitiligo, crisaborole, PDE-4 inhibitor


Vitiligo is a common disorder of skin pigmentation resulting from autoimmune destruction of melanocytes. A variety of topical and systemic treatment options have been tried with varying success. Here we describe the case of a man with refractory vitiligo successfully treated with topical crisaborole ointment.

Crisaborole ointment is a topical phosphodiesterase (PDE)-4 inhibitor recently FDA-approved for the treatment of atopic dermatitis. Previous literature has discussed the possible role of systemic PDE-4 inhibitors in vitiligo; herein, we discuss the ability of topical crisaborole to accelerate repigmentation in treatment-resistant vitiligo.


1. Huff S, Gottwald L. Repigmentation of Tenacious Vitiligo on Apremilast. Case Reports in Dermatological Medicine. 2017. DOI: 10.1155/2017/2386234

2. Kailas A. Crisaborole: a new and effective nonsteroidal topical drug for atopic dermatitis. Dermatologic Therapy. 2017;30(5). DOI: 10.1111/dth.12533

3. Eichenfield LF, Call RS, et al. “Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.” JAAD. 77(4), 2017 Oct